Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
Metastasis02:30

Metastasis

5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
Cancer Cell Migration through Invadopodia01:35

Cancer Cell Migration through Invadopodia

2.3K
Invadosome is a broad category of cell surface structures with proteolytic activity that  degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
2.3K
Tumor Progression02:07

Tumor Progression

6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retraction Note: NSD2 targeting reverses plasticity and drug resistance in prostate cancer.

Nature·2026
Same authorSame journal

ERG orchestrates a dedifferentiation-senescence-inflammation triad in prostate cancer.

Molecular cancer research : MCR·2026
Same author

The WHO Classification of Genetic Tumour Syndromes: Considerations for Genetics.

Clinical genetics·2026
Same author

Intermediate clinical endpoints as surrogates for overall survival after salvage prostatectomy.

BJU international·2026
Same author

Progressive matrix stiffening of tyramine-modified silk fibroin hydrogels governs stage-specific pulmonary fibroblast activation.

bioRxiv : the preprint server for biology·2026
Same author

A forward genetic screen identifies Sirtuin1 as a driver of neuroendocrine prostate cancer.

The Journal of experimental medicine·2026
Same journal

Comprehensive multi-omic profiling of desmoplastic small round cell tumors identifies targetable pathways with therapeutic opportunities.

Molecular cancer research : MCR·2026
Same journal

CELF2 is a tumor suppressor that modulates SLC7A11 and promotes ferroptosis in stomach adenocarcinoma.

Molecular cancer research : MCR·2026
Same journal

MYC-Mediated USP39 Upregulation Stabilizes SRSF1 in Pancreatic Cancer.

Molecular cancer research : MCR·2026
Same journal

Ceramide-induced endoplasmic reticulum stress reveals a targetable vulnerability in endocrine therapy-resistant breast cancer.

Molecular cancer research : MCR·2026
Same journal

Mapping the Subtype-Specific PARP1 ADP-ribosylated Proteome in Breast Cancer Cells.

Molecular cancer research : MCR·2026
See all related articles

Related Experiment Video

Updated: May 29, 2025

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.0K

ATAD2 Drives Prostate Cancer Progression to Metastasis.

Anindita Dutta1, Antonio Rodriguez-Calero2,3, Kacey Ronaldson-Bouchard4

  • 1Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.

Molecular Cancer Research : MCR
|February 5, 2025
PubMed
Summary
This summary is machine-generated.

ATPase family AAA domain containing 2 (ATAD2) drives prostate cancer bone metastasis. Inhibiting ATAD2 reduced cancer spread and growth, identifying it as a potential therapeutic target for advanced prostate cancer.

More Related Videos

Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs
10:32

Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs

Published on: December 19, 2019

10.8K
Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model
06:32

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

Published on: November 4, 2022

4.5K

Related Experiment Videos

Last Updated: May 29, 2025

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.0K
Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs
10:32

Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs

Published on: December 19, 2019

10.8K
Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model
06:32

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

Published on: November 4, 2022

4.5K

Area of Science:

  • Oncology
  • Molecular Biology
  • Epigenetics

Background:

  • Metastasis is a primary cause of cancer mortality, particularly in prostate cancer.
  • The mechanisms driving cancer progression to metastasis are not fully understood.
  • ATPase family AAA domain containing 2 (ATAD2), an epigenetic regulator, is overexpressed in cancers and linked to poor outcomes.

Purpose of the Study:

  • To investigate the role of ATAD2 in prostate cancer bone metastasis.
  • To determine if ATAD2 is a potential therapeutic target for metastatic prostate cancer.

Main Methods:

  • Utilized genetically engineered mouse models of prostate cancer bone metastasis.
  • Analyzed multiple independent human patient cohorts.
  • Conducted functional studies using mouse bone metastatic cell lines and organ-on-a-chip bone invasion assays.

Main Results:

  • ATAD2 was significantly enriched in bone metastases compared to primary prostate tumors.
  • ATAD2 expression correlated with increased metastasis development and MYC pathway activation.
  • Inhibition of ATAD2 decreased prostate cancer metastasis and bone growth in experimental models.

Conclusions:

  • ATAD2 is a key driver of prostate cancer progression and bone metastasis.
  • Targeting ATAD2 represents a promising therapeutic strategy for metastatic prostate cancer.